PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)  by Walzer, S et al.
A258 Paris Abstracts
multi-center, observational study on GIST patients treated with Imatinib between the 
availability on the French Market and the end of the 2008. Centers were randomly 
selected in national ﬁles of oncologists, gastrointestinal surgeons and specialists. The 
planned follow-up duration was three years. A case report form had to be completed 
at inclusion and during each follow-up visits. Quality of life was assessed using QLQ-
C30 and SF36 questionnaires. RESULTS: Thirty on 51 selected centers enrolled at 
least one patient and 139 patients were included (as of June 2009). The median age 
of disease onset was 58 years (range 21–86). 42% were metastatic at diagnosis. 
Primary tumors were most often stomach (48%), or bowel (34%). At diagnosis 86% 
of patients had a tumor size over 5 cm. 68% of patients had surgery of the primary 
tumor before starting Imatinib. 68% of patients were considered as high risk of relapse 
according the Miettinen classiﬁcation. For 99% of the patients, Imatinib was given at 
an initial dosage of 400 mg, 1% at 300 mg. Compliance was superior to 90% for 
99% of patients. With a median follow-up of 2.1 years, two-years overall survival 
from ﬁrst treatment with Imatinib was 83.9% (CI95%: [74.5%–90.1%]). CONCLU-
SIONS: EPIGIST is still an ongoing survey. Current results conﬁrm previous published 
data on survival in GIST treated with Imatinib in an unselected cohort of patients 
outside of a clinical trial.
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OBJECTIVES: The purpose of the study was to evaluate the relative efﬁcacy of dif-
ferent medication interventions in the treatment of metastatic renal cell carcinoma 
(mRCC) using a Bayesian mixed treatment comparison (MTC) model. METHODS: 
A systemic review was undertaken to identify randomized controlled trials assessing 
the efﬁcacy of bevacizumab, sorafenib, sunitinib, temsirolimus, and everolimus as 
stand alone therapy or in combination with interferon Alfa. The search was conducted 
within seven electronic data bases (CinAhl, AMED, Cochrane Library, Embase, 
Medline, ASCO, and Clinical trials.gov) for English language publications from incep-
tion to June 6th 2009. The Progression Free Survival (PFS) was outcome of interest in 
this study. Bayesian MTC was performed for evidence synthesis using both ﬁxed and 
random effect models. With MTC, the relative treatment effect of one intervention 
compared with another can be obtained in the absence of head-to-head evidence. 
RESULTS: Sunitinib yielded an effect size of 0.75 (95% credible interval: 0.61–0.93) 
compared to bevacizumabinterferon; 0.43 (0.31–0.75) compared to bevacizumab; 
0.54 (0.37–0.85) compared to sorafenib; 0.74 (0.57–0.96) compared to temsirolimus; 
and 0.97 (0.57–1.57) compared to everolimus. CONCLUSIONS: The relative efﬁcacy 
of sunitinib was better than all medication interventions on PFS except everolimus in 
the treatment of mRCC.
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OBJECTIVES: In the Netherlands, additional funding of expensive hospital drugs 
requires an assessment of real-world cost-effectiveness within 3 years after implement-
ing. We explored the use and limitations of real-world data for the economic evalua-
tion of oxaliplatin plus standard adjuvant treatment in stage III colon cancer.            
METHODS: Real-world data were gathered from the Dutch population-based Cancer 
Registry supplemented with data from medical records. Patients additionally treated 
with oxaliplatin (N  101) were compared to patients receiving only standard adjuvant         
therapy (N  105). Moreover, comparisons were made between our ﬁndings and         
results from the randomised controlled trial (RCT) that demonstrated a signiﬁcantly 
improved disease-free survival with oxaliplatin, on which current Dutch treatment   
guidelines are based. RESULTS: Patients receiving oxaliplatin are signiﬁcantly younger 
and have fewer comorbidities than patients receiving alternative chemotherapy. 
Median follow-up time of the study was 26.6 months. The adjusted hazard ratio for   
disease-free survival of 0.84 indicated that oxaliplatin was more effective. However, 
the 95% conﬁdence interval of 0.35–2.03 revealed large uncertainty about the actual 
effectiveness in daily clinical practice. Moreover, residual confounding could not be 
ruled out. On the other hand, patient characteristics, treatment patterns, comparator 
arm, dosages, toxicities, resource use, costs and disease-free survival outcomes 
obtained in clinical daily practice showed great similarities with the RCT based data 
and results. During our study, extended 6-year RCT follow-up results became avail-
able which conﬁrmed previous ﬁndings. CONCLUSIONS: Insight into patient char-
acteristics, treatment patterns, dosage and toxicities observed in daily clinical practice 
is very useful in determining the extent to which RCT results are generalisable to a 
real-world setting. However, outcomes research alone does not necessarily lead to 
internally valid and precise estimates of effectiveness and cost-effectiveness. In these 
situations, assessment of real-world cost-effectiveness should be based on a careful 
synthesis of RCT results and real-world observations.
PCN13
A COMPARATIVE EFFECTIVENESS ASSESSMENT OF FIRST-LINE 
BEVACIZUMAB  INTERFERON ALPHA-2A VS SUNITINIB IN 
METASTATIC RENAL CELL CARCINOMA
Mickisch GH1, Schwander B2, Escudier B3, Bellmunt J4, Maroto P5, Porta C6, Walzer S7, 
Siebert U8
1Center of Operative Urology Bremen, Bremen, Germany, 2AiM GmbH Assessment in 
Medicine, Schopfheim, Germany, 3Institut Gustave Roussy, Villejuif, France, 4University 
Hospital del Mar. UPF, Barcelona, Spain, 5Hospital de la Santa Creu i Sant Pau, Barcelona, 
Spain, 6IRCCS San Matteo University Hospital Foundation, Pavia, Italy, 7F. Hoffmann-La 
Roche Pharmaceuticals AG, Basel, Switzerland, 8UMIT—University for Health Sciences, 
Medical Informatics and Technology, Hall i.T, Austria
OBJECTIVES: Bevacizumab (BEV)  Interferon-alpha-2a (IFN-A) and sunitinib (SUN) 
have shown signiﬁcant increase in progression free survival (PFS) compared to IFN-A 
in ﬁrst-line metastatic renal cell carcinoma (mRCC) therapy. There is no head-to-head 
evidence available comparing both regimens, however there is an increasing need to 
assess and compare the relative efﬁcacy and effectiveness of both therapy approaches.          
METHODS: We applied the widely accepted indirect comparison method (Bucher 
et al. J Clin Epidemiol 1997) to PFS data of the pivotal phase III trials, that is, the 
unadjusted investigator-assessed PFS hazard ratios (HR) for BEV      IFN-A vs. IFN-A 
(0.63) and for SUN vs IFN-A (0.52). To enable valid indirect comparison, the IFN-A 
control arms of both trials have been standardised by recalculating the indirect HR 
and transferring them into direct HR estimates using the cross-trial proportions. In          
addition, we adjusted for effects of down-dosing and patient compliance based on 
published evidence. Sensitivity analyses on adjustment components have been per-
formed. RESULTS: The unadjusted indirect efﬁcacy comparison resulted in a statisti-      
cally non-signiﬁcant PFS difference of SUN vs BEVIFN-A (HR: 0.82; 95% CI: 
0.64–1.06; p  0.13). Standardising the IFN arms and simulating realistic scenarios         
for SUN down-dosing and patient compliance results in similar PFS HRs for BEV       IFN-
A (HR: 0.63) and Sunitinib (HR: 0.64) as compared to IFN alone. The adjusted indi-   
rect PFS HR of SUN vs BEV  IFN-A was 1.025 (95% CI: 0.81–1.30; p  0.83). 
Results were mostly inﬂuenced by IFN-A control arm adjustment, followed by patient 
compliance and down-dosing. CONCLUSIONS: Based on our comparative effective-
ness evaluation in ﬁrst-line mRCC therapy, there is no statistically signiﬁcant evidence 
for a difference in efﬁcacy and effectiveness regarding PFS between    BEVIFN-A and 
SUN. These ﬁndings imply that additional treatment decision criteria such as tolerabil-
ity need to be considered to guide treatment decisions.
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OBJECTIVES: New treatment options are needed for advanced NSCLC offering 
improved progression-free (PFS) and overall survival (OS) over standard chemother-
apy. Bevacizumab, a humanised monoclonal antibody (MAb) against VEGF, plus 
chemotherapy increases PFS and OS in advanced NSCLC patients versus chemother-
apy alone4–5. Cetuximab, a MAb targeting EGFR, showed signiﬁcant OS when com-
bined with chemotherapy3. This study compared the clinical beneﬁts for NSCLC 
patients treated with BCG or BCP to CVC using indirect treatment comparison (ITC) 
methodology. METHODS: In the absence of head-to-head trials, ITC1–2 was per-
formed on patients with non-squamous NSCLC comparing the relative beneﬁt of 
ﬁrst-line therapies BCG/BCP versus CVC by hazard ratios (HR) adjusted for differ-
ences in underlying chemotherapy and populations. Where HRs were not reported, 
HRs1 and standard errors6 were estimated. Based on the ITC a statistical disease model 
was developed to estimate the adjusted time in PFS and OS. RESULTS: ITC-estimated 
HRs for the primary endpoints in AVAiL4 and E45995 showed that the adjusted PFS 
HR for BCG versus CVC was 0.80 resulting in an expected time spent in PFS for BCG 
of 9.62 versus 7.99 months for CVC. Model-derived data showed BCP treatment in 
patients with adenocarcinoma histology resulted in adjusted BCP HR of 0.89 versus 
CVC. Model data also showed that BCP patients experienced on average, 19.55 
versus. 17.57 months (CVC) of OS. Sensitivity analyses conﬁrmed the robustness of 
these ﬁndings. CONCLUSIONS: Interpretation of ITC ﬁndings are limited due to 
cross-study heterogeneity. However results show that BCG or BCP therapy in patients 
with advanced non-squamous NSCLC brings a superior beneﬁt in terms of OS and 
PFS compared with CVC therapy.
